{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:25:04Z","timestamp":1768980304257,"version":"3.49.0"},"reference-count":17,"publisher":"ALUNA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>Autoimmune encephalitis associated with anti-LGI1 antibodies (ang. leucine-rich glioma- inactivated 1) is one of the most common forms of limbic encephalitis. The aim of this paper was to present two cases of this disease with different clinical course and prognosis. We described the medical history of a 64-year-old man and a 75-year-old woman in whom the presence of anti-LGI1 antibodies in serum and\/or cerebrospinal fluid was detected. Both patients had typical facial-brachial dystonic seizures, memory impairment and hyponatremia. In the first case, in the early phase of the disease, MRI showed bilateral changes in the temporal lobes (mainly in the hippocampi), while in the second case, neuroimaging did not show typical changes for autoimmune encephalitis \u2013 vascular and atrophic changes dominated. In the first case, combined therapy (steroids and intravenous immunoglobulins) was used and significant improvement was achieved. In the second case, only intravenous immunoglobulins were used. Differential diagnosis of rapidly progressing neurological disorders should include autoimmune encephalitis. One of the forms of this disease is autoimmune encephalitis with the presence of anti-LGI1 antibodies, which should always be suspected in patients with dystonic facial-brachial seizures and memory disorders, especially with concomitant hyponatremia. Determination of antineuronal antibodies should be a standard procedure in such cases. Fast and accurate diagnosis allows for the initiation of effective treatment. Oncological vigilance should also be maintained \u2013 in some patients the presence of cancer is detected.<\/jats:p>","DOI":"10.36740\/merkur202506116","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:44:57Z","timestamp":1768934697000},"page":"816","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune encephalitis with LGI1 antibodies: a report of two cases"],"prefix":"10.36740","author":[{"given":"Aleksander","family":"Gawda","sequence":"first","affiliation":[{"name":"FACULTY OF MEDICINE, POZNAN UNIVERSITY OF MEDICAL SCIENCE, POZNAN, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Roszak","sequence":"additional","affiliation":[{"name":"STUDENT SCIENTIFIC ASSOCIATION AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Sierakowska","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF FAMILY MEDICINE AND PUBLIC HEALTH, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND; DEPARTMENT OF PSYCHIATRY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Piotrowiak","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF NEUROLOGY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szczerbaniewicz","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF NEUROLOGY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND; DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Gawda","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF NEUROLOGY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND; DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"\u0141abuz-Roszak","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Al-Attas AA, Eshetaiwe SE, Alnahdi MA, Nassar HM, Althobaiti AH. Rituximab for leucine-rich glioma-inactivated 1 (LGI1) antibody-related super-refractory status epilepticus: a case report and literature review. Cureus. 2025;17(3):e81094. doi: 10.7759\/cureus.81094.","DOI":"10.7759\/cureus.81094"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Otiniano-Sifuentes R, Cuba Antezana A, De La Cruz Ramirez WF, Pacheco-Barrios K, Segura Chavez DA. Case report: anti-LGI1 limbic encephalitis associated with anti-thyroid autoantibodies. Front Neurol 2021;11:620483. doi: 10.3389\/fneur.2020.620483.","DOI":"10.3389\/fneur.2020.620483"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Wang M, Cao X, Liu Q, Ma W, Guo X, Liu X. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat 2017;13:1589\u20111596. doi:10.2147\/NDT.S136723.","DOI":"10.2147\/NDT.S136723"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Rodriguez A, Klein CJ, Sechi E, Alden E, et al. LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry. 2022;93(3):309-315. doi: 10.1136\/jnnp-2021-327302.","DOI":"10.1136\/jnnp-2021-327302"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Yaqoob A, Dar W, Wani M, Asimi R, Raina A, Ganie H, Chandra A. LGI1\u2011antibody associated autoimmune encephalitis complicated by primary polydipsia. Ann Indian Acad Neurol 2022; 25(1):161-163. doi:10.4103\/aian.AIAN_141_21.","DOI":"10.4103\/aian.AIAN_141_21"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Gadoth A, Nisnboym M, Alcalay Y, Zubkov A, Schwartz I, Schwartz D, Abboud M, Rubinek T, Yossepowitch O, Weinstein T. Electrolyte imbalance in anti-LGI1 encephalitis: it is not all in your head. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200155. doi: 10.1212\/NXI.0000000000200155.","DOI":"10.1212\/NXI.0000000000200155"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Labuz-Roszak B, Sierakowska A, Roszak M. Autoimmunologiczne zapalenie mozgu z obecno\u015bci\u0105 przeciwcia\u0142 anty-NMDAR \u2013 ro\u017cnorodno\u015b\u0107 objawow klinicznych. [Autoimmune encephalitis with anti-NMDAR antibodies \u2013 variety of clinical manifestations]. Aktual Neurol. 2023; 23(1):30-35. doi: 10.15557\/AN.2023.0005. (Polish)","DOI":"10.15557\/AN.2023.0005"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Cheng CC, Sung JY, Huang CS. LGI1 positive paraneoplastic limbic encephalitis: A case report of atypical presentation. J Med Cases 2021;12(10):417-420.","DOI":"10.54029\/2021auz"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Abunada M, Nierobisch N, Ludovichetti R, Simmen C, Terziev R, Togni C, Michels L, Kulcsar Z, Hainc N. Autoimmune encephalitis: Early and late findings on serial MR imaging and correlation to treatment timepoints. Eur J Radiol Open. 2024; 12: 100552. doi: 10.1016\/j.ejro.2024.100552. (Polish)","DOI":"10.1016\/j.ejro.2024.100552"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Lian X, Zheng K, Chen W, Li D, Xue F, Wang G. Autoimmune encephalitis related to LGI1 antibodies with negative MRI study: Description of two cases. Med Clin (Barc). 2024;162(1):35-38. doi: 10.1016\/j.medcli.2023.06.024.","DOI":"10.1016\/j.medcli.2023.06.024"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Cui LL, Boltze J, Zhang Y. Positive LGI1 antibodies in CSF and relapse relate to worse outcome in anti-LGI1 encephalitis. Front Immunol. 2021;12:772096. doi: 10.3389\/fimmu.2021.772096.","DOI":"10.3389\/fimmu.2021.772096"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Gomes Ferreira M, Lapresa Alcalde V, Garcia Sanchez MH, Hernandez Hernandez L, Doyague Sanchez MJ. Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis: A case report. Medicine (Baltimore). 2018;97(31):e11325. doi: 10.1097\/MD.0000000000011325.","DOI":"10.1097\/MD.0000000000011325"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Roberto KT, Espiritu AI, Fernandez MLL, Gutierrez JC. Electroencephalographic findings in antileucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis: A systematic review. Epilepsy Behav. 2020;112:107462. doi: 10.1016\/j.yebeh.2020.107462.","DOI":"10.1016\/j.yebeh.2020.107462"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, Shi J, Tian J. Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis: a systematic review. Front Neurol. 2022;12:791014. doi: 10.3389\/fneur.2021.791014.","DOI":"10.3389\/fneur.2021.791014"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Kong X, Gong X, Li A, Liu Y, Li X, Li J, Zhou D, Hong Z. Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: A meta-analysis. Ann Clin Transl Neurol. 2023; 10(9): 1578-1589. doi: 10.1002\/acn3.51847.","DOI":"10.1002\/acn3.51847"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Zhong R, Chen Q, Zhang X, Zhang H, Lin W. Relapses of anti-NMDAR, anti-GABABR and anti-LGI1 encephalitis: a retrospective cohort study. Front Immunol. 2022; 13: 918396. doi: 10.3389\/fimmu.2022.918396.","DOI":"10.3389\/fimmu.2022.918396"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Hang HL, Zhang JH, Chen DW, Lu J, Shi JP. Clinical characteristics of cognitive impairment and 1-year outcome in patients with anti-LGI1 antibody encephalitis. Front Neurol 2020; 11: 852. doi: 10.3389\/fneur.2020.00852.","DOI":"10.3389\/fneur.2020.00852"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:45:00Z","timestamp":1768934700000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i6net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.36740\/merkur202506116","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}